Altogether, our study supports the clinical development of HDAC3 inhibitors based not only on their direct, anti-MM effect, but also on their indirect effects on the BM milieu, resulting in decreased MM cell growth and survival. This evidence concerns the gene HDAC3 and Miyoshi myopathy.